Sanofi and Denali Therapeutics ink 1.125bn deal in neurology/inflammation
Sanofi has acquired the global commercialisation rights for two preclinical programmes from Denali Therapeutics.
ProQR in licence deal with Ionis Pharmaceuticals
Dutch ProQR NV has licensed global commercialisation rights to IONIS-RHO-2.5Rx (QR-1123) from Ionis Pharmaceuticals, to treat autosomal dominant retinitis pigmentosa (adRP)
Newron bags 40m EIB loan
The EIB has agreed to support Italian CNS drug developer Newron Pharmaceuticals with up to 40m to support the development of the company’s late-stage pipeline.
TES Pharma presents new treatment approach towards AKI and NALFD
TES Pharma has presented a novel treatment approach for acute kidney injury and non-alcoholic fatty liver disease in Nature.
MEPs vote for ban of single-use plastics
The European Parliament has approved measures that could lead to a ban of the top 10 single use plastic products that contribute to marine littering by 2021.
AstraZeneca and Innate Pharma in US$5bn oncology deal
AstraZeneca plc has extended its immunoncology pipeline by an extension of its partnership with French Innate Pharma SA.
Takeda strikes US$640m deal with Enterome
French Enterome SA has added a second licence agreement with Takeda to its deal portfolio, projecting possible payments of US$640m.
EMA recommends four biologicals for market
The European Medicines Agency delays the EU approval of Nivolumab/Ipilimumab in NSCLC and greenlights four biotherapeutics to be marketed in the EU.
Companies at EFIB set to drive the bioeconomy
Industrial biotech innovations, presented in at the 11th EFIB in Toulouse, could become the key enabler set to save our planet if supported appropriately.
Oxford Nanopore wins over Amgen
Oxford Nanopore Technologies has impressed Amgen with its genetic sequencing technology. The US biopharma major has invested £50m in the Oxford-based company.